Novo Nordisk A/S
ANTI-NKG2A ANTIBODIES AND USES THEREOF

Last updated:

Abstract:

Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.

Status:
Application
Type:

Utility

Filling date:

29 Apr 2019

Issue date:

15 Aug 2019